neues von biomira - 500 Beiträge pro Seite

[TheSimpson]

Biomira`s President and CEO appointed board member of Biotechnology Industry Organization

EDMONTON, April 20 /CNW-PRN/ - Biomira Inc. (NASDAQ: BIOM - news; TSE: BRA - news) today announced the election of President and CEO Alex McPherson, MD, PhD, to the Biotechnology Industry Organization (BIO) Board of Directors and the Emerging Companies Section Governing Body for the 2000-2001 term.

``I am greatly honored to be chosen to serve once again on the Board of this important organization,`` commented Dr. McPherson. ``BIO plays a key role in bringing together the resources and expertise to meet critical challenges in the biotech industry.``

BIO is the leading source of biotech information for industry leaders, policy-makers, media and the general public. BIO serves as an arena where industry representatives can meet, monitor and regulate legislative activities, and discuss the latest breakthroughs in biotechnology research.

Dr. McPherson previously served one year as a Board Member of BIO during the 1999-2000 term and was a Board Member of the Emerging Companies Section both in 1998-1999 and 1999-2000.

``We are pleased to have Dr. McPherson join us once again as a member of our Board,`` commented Carl Feldbaum, President of BIO. ``He is a valuable asset to our organization and we value his perspective on the industry.``

Based in Washington, D.C, BIO engages in lobbying, advocacy, communications and new business development related to the biotech industry. Established in 1993, today it includes more than 850 member companies.

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. The commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. We are The Cancer Vaccine People(TM).

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of clinical trials, the efficacy of products or the availability of capital. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company`s expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

SOURCE: Biomira Inc.

[NoamX]

Hallo Mr. Simpson,

ich denke, man muß BIOM als Lotterielos betrachten. Da es sich um eine Zwei-Produkt Entwicklungsfirma handelt,
ist Gedeih und Verderb vom Erfolg der Phase 3 Studien abhängig. Wie gut da die Chancen wirklich sind, kann ich mangels
Fachkenntniss nicht wirklich beurteilen (vielleicht jemand anderes hier?).
Offenbar ist jedoch die Finanzierung der Studien gesichert, was einen Buyout oder eine Verwässerung der Aktien verhindern sollte.

Das Risiko erhöht gleichzeitig die finanziellen Chancen. Eine erfolgreiche Phase 3 Studie würde den Wert von BIOM und damit
den Aktienkurs drastisch nach oben drücken, da erhebliches Marktpotenzial in dem Theradope steckt. BLP-25 hat
möglicherweise noch mehr Potenzial.

Lesenswert:
http://www.siliconinvestor.com/stocktalk/msg.gsp?msgid=13362…

http://www.siliconinvestor.com/stocktalk/msg.gsp?msgid=13327…

NoamX

[TheSimpson]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[TheSimpson]

jetzt geht es los !!!!!!!!Related Quotes

BIOM
BRA.TO
11 1/4
16.90
+3 1/8
+4.80

delayed 20 mins - disclaimer


Monday May 8, 8:01 am Eastern Time
Company Press Release
SOURCE: Biomira Inc.
FDA grants fast track status for THERATOPE(R) vaccine
EDMONTON, May 8 /CNW-PRN/ - Biomira Inc. (Nasdaq: BIOM - news; TSE: BRA - news) today announced the US Food & Drug Administration has designated the investigation of THERATOPE® vaccine for metastatic breast cancer as a Fast Track Drug development program. The FDA`s fast track programs are designed to facilitate the development and expedite review of drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

``We have reviewed your request and concluded that it meets the criteria for the Fast Track designation,`` states a recent letter from the FDA to Biomira. ``Therefore, we are designating as a Fast Track Drug Product development program the investigation of THERATOPE® vaccine as an adjunct to the first line combination chemotherapy in responding patients with metastatic breast cancer for its effect on the prolongation of the time-to-disease progression and increase in overall survival.``

Earlier studies to date have suggested THERATOPE® vaccine offers significant survival benefits to patients with metastatic breast cancer over today`s standard treatments alone. In one arm of two parallel prospectively randomized trials, THERATOPE® vaccine-treated patients had a median survival of 26.5 months compared to 9.2 months in a retrospective control group. Biomira is currently evaluating THERATOPE® vaccine in a pivotal Phase III trial with 900 evaluable patients. The Company expects to complete enrolment by year`s end 2000.

``This is a significant milestone for the Company, highlighting the importance of new drugs such as THERATOPE® vaccine to one day address a sizeable unmet need in this patient population,`` commented Alex McPherson, MD, PhD, President & CEO of Biomira. ``We believe our vaccine will be able to provide a new treatment option for women with breast cancer that has the potential to both extend and improve the quality of their lives.``

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. The commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. We are The Cancer Vaccine People(TM).

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting product approvals, the timing of clinical trials, the efficacy of products or the availability of capital. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company`s expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

SOURCE: Biomira Inc.



--------------------------------------------------------------------------------
More Quotes and News: Biomira Inc (NasdaqNM:BIOM - news; Toronto:BRA.TO - news)
Related News Categories: biotech, medical/pharmaceutical